A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma
British Journal of Haematology - United Kingdom
doi 10.1111/bjh.13637
Full Text
Open PDFAbstract
Available in full text
Categories
Date
August 7, 2015
Authors
Publisher
Wiley